Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
Article in PharmacoEconomics (September 2022)
The most recent citing publications are shown below. View all 8 publications that cite this research output on Dimensions.
Article in PharmacoEconomics (September 2022)
Article in Frontiers in Pharmacology (April 2022)
Article in Journal of Cardiac Critical Care TSS (January 2022)